S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook Weakens
Key Takeaways The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead ...
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors
Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for ...
Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...
Seeking Alpha7d
Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A Downgrade
Eli Lilly's operational performance is strong ... shares have seen downside of 14.8% at a time when the S&P 500 is up 2.6%. The picture isn't as bad when we compare the data to my original ...
Wall Street mostly rises after encouraging inflation data despite Lilly’s drag
Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...
S&P 500 edges higher, Nasdaq dips in choppy session as inflation data eyed
"Although the tariff news has seen investors add a few basis points to the total cuts expected for 2025, there is scope for ...
Microsoft, Applied Digital, Rigetti Computing, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market experienced mixed results on Tuesday. The Dow Jones index climbed over 220 points to 42,518.28, while ...
Morningstar4d
Mounjaro and Zepbound sales disappoint, and Eli Lilly's stock is dropping
are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make it the S&P 500 index's SPX worst performer.